Delve into this session featuring selected clinical cases from PCR London Valves 2024, focusing on the use of TAVI to address aortic regurgitation. Gain insights into the management of pure native aortic regurgitation in surgically unfit patients, the treatment of aortic regurgitation in patients with left...

Explore the latest research and insights in the field of aortic valve interventions through this featured research session. Discover cutting-edge studies on topics ranging from one-year outcomes after TAVI in different valve types to the impact of frailty and mobility on post-TAVI outcomes, and much more....

Delve into this session featuring selected clinical cases from PCR London Valves 2024, focusing on the use of transcatheter edge-to-edge repair (TEER) for the treatment of tricuspid regurgitation. Explore innovative techniques such as the use of the Pascal device in a patient with dextrocardia, the combination...

Dive into a collection of captivating clinical cases where the cardiologist and surgeon collaborate to tackle complex cardiovascular challenges. From direct vision TAVI implantation during left ventricular assist device surgery to managing iatrogenic annulus rupture during TAVR, this session offers invaluable insights into the art of...

Explore the global challenge of hypertension, affecting one in three adults, and the strategies for screening, diagnosis, and management, including lifestyle modifications, pharmacotherapy, and device-based treatments, as outlined by Sofie Brouwers.

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.

This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.